What to Expect

Participating in LIFT-AD

The LIFT-AD trial is seeking to enroll approximately up to 300 participants with mild to moderate Alzheimer’s disease in the United States. Qualified participants will be randomly assigned to receive fosgonimeton or placebo. Participation in the study takes about eight months including approximately six months of treatment duration. During the treatment period, you or your caregiver will administer daily subcutaneous injections using the provided prefilled syringes (i.e. small injection under the skin that you can take at home; the injection is prepared and ready for administration).


Upon completion of the LIFT-AD trial, interested participants are eligible to enroll in the Open Label Extension study of fosgonimeton. This study ensures participants will receive the active drug.

What is Involved in the Trials?